Clinical trial NCT02418299: Er:YAG Laser Treatment for Female Stress and Mixed Urinary Incontinence (IncontiLase)
Official title: Prospective, Single Centre Study of Er:YAG Laser Treatment for Female Stress and Mixed Urinary Incontinence (IncontiLase)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Female Stress Urinary Incontinence
Mixed Incontinence, Urge and Stress
Keywords: urinary incontinence
Er:YAG laser
Lead sponsor: Juna d.o.o.
Sponsor class: INDUSTRY
First posted: 2015-04-16
Enrollment: 175
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to evaluate the effect of a non-invasive Er:YAG thermal laser therapy in treating female stress and mixed urinary incontinence.

Detailed description: Urinary incontinence (UI) is a common disorder that affects women of various ages and impacts all aspects of life. Therapeutic approaches range from conservative therapy, which is heavily dependent on patient compliance, to different, more invasive, surgical procedures.

The aim of the study was to evaluate the non-invasive erbium:yttrium-aluminum-garnet (Er:YAG) laser treatment (IncontiLase) as a potential treatment strategy for stress UI (SUI) and mixed UI (MUI). The treatment works by thermally affecting vaginal mucosa, with an emphasis on the anterior vaginal wall, resulting with partial denaturation of collagen fibres and stimulation if new collagen formation, all of which leads to firmer support for the urethra and the improvement of incontinence symptoms.

The investigators included 175 women with newly diagnosed SUI (66% of women) and MUI (34 %), respectively and performed on average 2.5±0.5 procedures in each woman separated by a two-month period, using Er:YAG laser. Patients were clinically examined and classified by incontinence types (SUI and MUI) and grades (mild, moderate, severe and very severe) using International Consultation on Incontinence Modular Questionnaire (ICIQ) and assessing Incontinence Severity Index (ISI): ISI before the therapy was 5.7±2.1 points. Treatment discomfort was measured at every session with visual analogue system pain scale, and adverse effects and patients' satisfaction were followed. Follow-ups were performed at two, six and twelve months after the treatment.

Eligibility criteria: Inclusion Criteria:

* clinically confirmed UI
* normal PAP smear (Papanicolaou cytology)
* negative urine culture
* integrity of the vaginal mucosa (without injuries or bleeding)

Exclusion Criteria:

* pregnancy
* intake of photosensitive drugs
* vaginal injuries or vaginal bleeding
* infection in the treated area
* clinical diagnosis of pure urge urinary incontinence

Primary outcomes:
measure: Change in the Incontinence Severity Index (ISI) calculated from the ICIQ-UI short form questionnaire
timeFrame: at baseline and 2, 6 and 12 months after treatment
Secondary outcomes:
measure: VAS index for the assessment of pain
timeFrame: at baat baseline and 2, 6 and 12 months after treatment
Other outcomes:
Locations:
Study officials:
affiliation: Juna d.o.o.
name: Urška Bizjak-Ogrinc, Dr
role: PRINCIPAL_INVESTIGATOR
References: